Evidence map›Paper›PMID 38318349›Full record

ArticleiScience2024

Antiviral response and HIV-1 inhibition in sickle cell disease.

Namita Kumari, Asrar Ahmad, Clemilson Berto-Junior, Andrey Ivanov, Fayuan Wen, Xionghao Lin, Sharmin Diaz, Iheanyi Okpala, James G Taylor, Marina Jerebtsova and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. EcoHIV Infection Promotes Atherosclerosis Progression in LDLR-Deficient Mice.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Namita KumariCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Asrar AhmadCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Clemilson Berto-JuniorCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Andrey IvanovCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Fayuan WenCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Xionghao LinCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Sharmin DiazCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Iheanyi OkpalaUniversity of Nigeria, Enugu, Nigeria.
James G TaylorCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.
Marina JerebtsovaDepartment of Microbiology, Howard University, Washington, DC, USA.
Sergei NekhaiCenter for Sickle Cell Disease, Howard University, Washington, DC, USA.

Funding

Sleep Disorders in Adults with Sickle Cell Disease: Frequency, Associations with Cardiovascular and Pain Indicators, and Responses to TreatmentU54MD007597 · NIMHD · HOWARD UNIVERSITY · PI William M. Southerland · 2019 to 2026
$37.7M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
X-ray Screening and Rapid Structure DeterminationP50AI150476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EMERMAN, MICHAEL · 2019 to 2021
$14.4M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African AmericansR01HL125005 · NHLBI · HOWARD UNIVERSITY · PI MARINA A JEREBTSOVA, SERGEI NEKHAI · 2014 to 2026
$6.7M
The role of HGFL in the sickle cell disease nephropathySC1HL150685 · NHLBI · HOWARD UNIVERSITY · PI JEREBTSOVA, MARINA A · 2019 to 2022
$1.5M
Acquisition of Orbitrap mass spectrometerS10OD028681 · OD · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2020 to 2020
$869k
NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R01 HL125005NHLBI NIH HHS SC1 HL150685NIAID NIH HHS P30 AI117970NIAID NIH HHS P50 AI150476NIH HHS S10 OD028681NIMHD NIH HHS U54 MD007597
6 · The paper itself

Abstract

Sickle cell disease (SCD) is characterized by hemolysis, vaso-occlusion, and ischemia. HIV-1 infection was previously shown to be suppressed in SCD PBMCs. Here, we report that HIV-1 suppression is attributed to the increased expression of iron, hypoxia, and interferon-induced innate antiviral factors. Inhibition of upregulated antiviral genes,

Indexed as

HematologyVirology

Identifiers

PMID38318349
PMCPMC10839265

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.